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Emerging resistance to trimethoprim/sulfamethoxazole (SXT) poses a serious threat to the 
treatment of Stenotrophomonas maltophilia infections. We determined the prevalence and 
molecular characteristics of acquired SXT resistance in recent clinical S. maltophilia iso-
lates obtained from Korea. A total of 252 clinical isolates of S. maltophilia were collected 
from 10 university hospitals in Korea between 2009 and 2010. Antimicrobial susceptibility 
was determined by using the CLSI agar dilution method. The sul1, sul2, and sul3 genes, 
integrons, insertion sequence common region (ISCR) elements, and dfrA genes were de-
tected using PCR. The presence of the sul1 gene and integrons was confirmed through se-
quence analysis. Among the 32 SXT-resistant isolates, sul1 was detected in 23 isolates 
(72%), all of which demonstrated high-level resistance (≥64 mg/L) to SXT. The sul1 gene 
(varying in size and structure) was linked to class 1 integrons in 15 of the 23 isolates (65%) 
harboring this gene. None of the SXT-susceptible isolates or the SXT-resistant isolates with 
a minimum inhibitory concentration of 4 and 8 mg/L were positive for sul1. Moreover, the 
sul2, sul3, and dfrA genes or the ISCR elements were not detected. The sul1 gene may play 
an important role in the high-level SXT resistance observed in S. maltophilia.
Key Words: Stenotrophomonas maltophilia, Trimethoprim/sulfamethoxazole, sul, Class 1 
integron
Received: July 8, 2014
Revision received: August 19, 2014
Accepted: December 1, 2014
Corresponding author: Seong Geun Hong
Department of Laboratory Medicine, CHA 
Bundang Medical Center, CHA University,
59 Yatap-ro, Bundang-gu, Seongnam  
463-712, Korea
Tel: +82-31-780-5463
Fax: +82-31-780-5476
E-mail: hlseo@cha.ac.kr
Some of this work was presented at the 
52nd Annual Meeting of the Korean Society 
for Laboratory Medicine, Muju, Korea, 
October 6-7, 2011 (Oral no. O-27).
© The Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/3.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
Stenotrophomonas maltophilia, a non-fermentative, gram-nega-
tive bacillus frequently found in community or hospital environ-
ments, has emerged as an important opportunistic pathogen; it 
is most commonly associated with respiratory infections in hu-
mans. The incidence of hospital-acquired S. maltophilia infec-
tions is increasing, and cases of community-acquired S. malto-
philia have also been reported [1, 2]. The treatment of S. malto-
philia infections is extremely difficult, owing to the intrinsic or ac-
quired resistance to multiple therapeutic drugs, the development 
of resistance during therapy, and the paucity of clinical therapeu-
tic data [3]. The recommended first-line agent in the treatment 
of S. maltophilia is trimethoprim/sulfamethoxazole (SXT), be-
cause of low incidence of resistance [1]. However, the treatment 
of S. maltophilia infections has become more problematic, with 
an increase in the acquired resistance to SXT [4, 5]. The sul genes 
are known to contribute to the resistance to SXT and have been 
reported to associate with the class 1 integrons and insertion se-
quence common region (ISCR) elements [6, 7]. Moreover, it has 
been reported that the dfrA genes, located in the gene cassettes 
of the class 1 integrons, lead to a high-level resistance to SXT [8]. 
However, sul1 has been detected in the SXT-susceptible S. 
maltophilia isolates [8-10]. In this study, we analyzed the pre-
dominant mechanisms underlying acquired SXT resistance in 
recent clinical S. maltophilia isolates obtained from Korea.
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 A total of 252 non-duplicate clinical isolates of S. maltophilia 
were collected from 10 university hospitals in Korea between 
2009 and 2010. The species were identified by using conven-
tional methods and/or the ATB 32GN system (bioMérieux, Marcy 
l’Etoile, France). The SXT susceptibility was determined by us-
ing the CLSI agar dilution method [11]. In order to assess the 
presence of sul genes and integrons in the isolates, PCR was 
performed with specific primers (sul1 [Forward, 5´-ATG GTG 
ACG GTG TTC GGC ATT CTG A-3´; Reverse, 5´-CTA GGC ATG 
ATC TAA CCC TCG GTC T-3´], sul2 [Forward, 5´-GAA TAA ATC 
GCT CAT CAT TTT CGG-3´; Reverse, 5´-CGA ATT CTT GCG GTT 
TCT TTC AGC-3´], sul3 [Forward, 5´-CAT TCT AGA AAA CAG 
TCG TAG TTC G-3´; Reverse, 5´-CAT CTG CAG CTA ACC TAG 
GGC TTT GGA-3´], and class 1 integron [Forward, 5´-GCC TGT 
TCG GTT CGT AAG CT-3´; Reverse, 5´-CGG ATG TTG CGA TTA 
CTT CG-3´]) [7, 12]. The presence of sul1 genes and integrons 
in the isolates was confirmed by sequencing. PCR analysis was 
performedby using ISCR-specific primers (ISCR-F, GCG AGT 
CAA TCG CCC ACT; ISCR-R, CGA CTC TGT GAT GGA TCG AA) 
to detect ISCR elements in the sul1-positive S. maltophilia iso-
lates [13], and additional PCR analysis was conducted by using 
certain primer combinations (e.g., sul1-F:ISCR-R or ISCR-F:sul1-
R). The presence of dfrA genes in the isolates was determined 
as per the method by Seputiene et al. [14]. The dfrA genes were 
grouped according to their sequence similarity, and the primers 
were designed for analyzing the dfrA genes. Four groups of 
primers were used to include all previously reported dfrA genes 
found in S. maltophilia [8].
 The sul genes were detected in 23 SXT-resistant isolates, but 
not in nine isolates exhibiting low-level SXT resistance (minimum 
inhibitory concentration [MIC] 4-8 mg/L). Moreover, sul was not 
detected in the 220 SXT-susceptible isolates. All the sul genes 
detected were found to be sul1 genes; the genes sul2 and sul3 
were not detected in the isolates. Fifteen of the 23 sul1-positive 
isolates harbored class 1 integrons (Table 1). The integrons var-
ied in size and structure. Six isolates possessed only intI1 and 
sul1. All the remaining integrons harbored the qacE△1 gene 
cassettes. One of these integrons also harbored the qac gene. 
Eight isolates contained one or two aminoglycoside-modifying 
enzyme genes (four isolates: aac6´-Ib; two isolates: aac6´-31-
like; one isolate: aacA7; one isolate: aacA7 and aadA4a). The 
PCR amplification products of ISCR were not detected, and the 
linkage of ISCR to the sul1 gene was not observed. No dfrA 
genes were detected.
 In a previous study, the overall resistance rate of the Korean S. 
maltophilia isolates to SXT was low (4%), while the resistance 
rate in one hospital was very high (26%) [15]. This result indi-
cates that the empirical selection of SXT for the treatment of S. 
maltophilia infections in some Korean hospitals may be inade-
quate for curing this infection completely. Additionally, Song et 
al. [10] reported that 19 (16%) of the 120 S. maltophilia isolates 
collected from three university hospitals in a particular region of 
Korea were found to be resistant to SXT. S. maltophilia isolates 
are often multidrug-resistant owing to the cumulative effects of 
intrinsic resistance and acquired resistance through integrons, 
transposons, and plasmids.
 Recently, SXT resistance in S. maltophilia has been reported 
to be associated with the sul1 gene carried by class 1 integrons 
[6, 7]. In addition, Toleman et al. [7] demonstrated that the ISCR 
elements linked to the sul2 genes could mediate SXT resistance 
in S. maltophilia. Hu et al. [8] hypothesized that the sul1 gene, if 
combined with the dfrA and sul2 genes, could contribute to SXT 
resistance. Interestingly, some investigators have reported the 
detection of the sul1 gene in SXT-susceptible S. maltophilia iso-
lates; however, the incidence of sul1 gene in the SXT-susceptible 
isolates was lower than that in the SXT-resistant isolates [8-10].
 In this study, of the 32 SXT-resistant S. maltophilia isolates, 
23 (72%) harbored the sul1 gene. None of the SXT-susceptible 
S. maltophilia isolates were found to yield positive sul1 PCR 
products. These results are similar to those of previous studies 
[6, 7]. It was not possible to detect the sul1 gene in the nine 
isolates that demonstrated low-level SXT resistance, although 
the SXT MIC of the sul1-positive isolates was found to be higher, 
exhibiting a range of 64-128 mg/L (Table 1). Previous studies 
reported that S. maltophilia isolates harboring the sul1 gene 
demonstrated high SXT MICs (>32 mg/L) [7, 8]. Accordingly, it 
is likely that high-level SXT resistance is associated with a spe-
cific and effective mechanism involving sul1.
 In contrast to high-level resistance, low-level SXT resistance 
was not associated with the sul genes. Low-level resistance may 
result from a much broader variety of biochemical mechanisms 
Table 1. Presence of sul genes and IntI1 and the corresponding 
association with trimethoprim/sulfamethoxazole (SXT) susceptibility
SXT
susceptibility
MIC range 
(mg/L)
N of isolates sul1
sul1 linked 
IntI1
Susceptible ≤0.06-2 220 0 ND
Resistant
   Low level 4-8 9 0 ND
   High level 64-128 23 23 (100%) 15 (65%)
sul2 and sul3 were not detected, regardless of susceptibility.
Abbreviation: ND, not detected.
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than those resulting in high-level resistance. Low antibiotic con-
centrations can select low-level antibiotic resistant variants, thus 
producing substantial stress in bacterial populations. This even-
tually influences the rate of genetic variation and the diversity of 
adaptive responses. The emergence of low-level resistance 
should be considered a warning signal, a hallmark of a possible 
evolutionary trend towards high-level, clinical resistance [16]. 
Further studies are needed in order to understand the mecha-
nisms and significance of low-level SXT resistance in S. malto-
philia.
 Usually, the class 1 integrons harbor the sul1 gene at the 3’ 
end [6, 7]. However, there are several reports on sul1-positive 
isolates not being associated with class 1 integrons [8-10]. In 
this study, class 1 integrons were not detected in eight high-
level SXT-resistant sul1-positive isolates.
 The sul2 gene has been reported to contribute to SXT resis-
tance [7, 9]. However, in this study and in another previous Ko-
rean study, the sul2 genes were not detected in the SXT-resis-
tant S. maltophilia clinical isolates [10]. The sul3 gene has not 
been associated with SXT-resistant S. maltophilia [7]. Contrary 
to the results reported by Tolman et al. [7], the ISCR elements 
and the sul2 gene were not detected in this study. Conse-
quently, the association of SXT resistance with the ISCR ele-
ments could not be confirmed or further elucidated in this 
study. Previous reports stated that the dfrA genes were identi-
fied in the SXT-resistant isolates and that the sul and dfrA genes 
could synergistically lead to high-level SXT resistance [8]. In the 
present study, we could not detect any dfrA genes. Whereas the 
presence of all types of the dfrA gene was not investigated, the 
primer pairs for the dfrA genes found in previous reports were 
included [8].
 Previous studies reported the presence of the 3´-end of class 
1 integrons, a semiconserved segment harboring the qacE△1 
and sul1 genes, encoding resistance to quaternary ammonium 
compounds and sulfonamides, respectively [7-9]. In this study, 
the qacE△1 genes along with the sul1 genes were detected in 
nine (60%) class 1 integrons; however, six (40%) class 1 inte-
grons harbored only the intI1 and sul1 genes. The gene cas-
settes within the class 1 integrons included the aminoglycoside 
resistance genes aac6’-Ib, aac6´-31-like, aacA7, and aacA7/
aadA4a.
 In summary, the present results indicate that excessive anti-
biotic usage in clinical settings is selecting SXT-resistant S. 
maltophilia strains through horizontal gene transfer. Clinical mi-
crobiology laboratories need to carefully monitor, using continu-
ous surveillance of SXT resistance rates, the possibility of S. 
maltophilia acquiring SXT resistance from mobile elements. The 
sul1 gene may play an important role in the mechanisms of 
high-level SXT resistance in S. maltophilia. Additionally, the sul1 
gene in the SXT-resistant S. maltophilia has been consistently 
associated with class 1 integrons. Although SXT resistance is 
uncommon in S. maltophilia, continuous monitoring of resis-
tance trends is necessary to ensure appropriate antimicrobial 
therapy.
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